Baxter International Inc., a global provider of sterile medication production and delivery, is investing approximately $100 million to expand its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany. This facility is operated by Baxter’s BioPharma Solutions (BPS), a business unit that specializes in the development and contract manufacturing of drug product for parenteral (injectable) pharmaceuticals. Construction is expected to begin in 2022 and be completed in 2024.
 
The strategic investment will expand the BPS manufacturing footprint and add state-of-the-art equipment designed to help products achieve stability and improved shelf life through lyophilization. Construction will also add an aseptic syringe filling line, enabling BPS to meet the growing demand for this delivery platform in both Europe and the U.S. Pre-filled syringes can enhance efficiency and ease-of-use for clinicians and have potential to minimize microbial contamination and reduce medication dosing errors.
 
“Baxter’s manufacturing site in Halle/Westfalen is one of the most advanced facilities in our global network and has seen significant growth over the last several years,” said Marie Keeley, general manager, Baxter BioPharma Solutions. “By making this investment, we are building on recent expansions to help ensure this facility can serve our partners at the highest level now and well into the future.”
 
Baxter’s Halle/Westfalen site is recognized as a world-class manufacturer of cytotoxic and highly potent drugs, offering dedicated clinical development through commercial production with integrated technologies and services, including barrier technology that helps maintain a high level of containment when manufacturing sensitive and sophisticated drugs, and broad sterile manufacturing capabilities The Halle/Westfalen facility is currently engaged in multiple collaborations to provide sterile manufacturing services for COVID-19 vaccines.